Rob Ashley of AmpliMed discusses the discovery and development of Imexon. Interview by Steve Carney.
Ashley
Robert A
RA
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D002626:Chemistry, Pharmaceutical / Q000379:methods* / Q000639:trends; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D004318:Doxycycline / Q000031:analogs & derivatives / Q000627:therapeutic use; D004345:Drug Industry / Q000191:economics / Q000379:methods / Q000639:trends*; D004357:Drug Synergism; D006588:Hexanones / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy; D013754:Tetracyclines / Q000627:therapeutic use; D000093542:Gemcitabine
D000970:Antineoplastic Agents; D006588:Hexanones; D013754:Tetracyclines; C117155:tetracycline CMT-3; D003841:Deoxycytidine; C014919:4-imino-1,3-diazabicyclo(3.1.0)hexan-2-one; D004318:Doxycycline; D000093542:Gemcitabine